...is also a venture partner with Forbion who has held executive positions at portfolio companies Xention Ltd....

...CEO. Diagnostic play PlaqueTec Ltd. (Cambridge, U.K.) named Tim Brears CEO. Brears was CEO of Xention Ltd....

...for 28 days in 20 patients with paroxysmal AF who have implanted pacemakers. Last year, Xention...
...and commercialize XEN-D0103 for AF, excluding the U.S. and Japan (see BioCentury, Oct. 7, 2013). Xention Ltd....

...prevent cough in patients with chronic obstructive pulmonary disease (COPD). Ario is a spinout of Xention Ltd....

...of XEN-D0501 in about 20 patients with chronic idiopathic cough. Ario is a spinout of Xention Ltd....

...the transient receptor potential vanilloid 1 ( TRPV1 ; VR1 ) receptor antagonist in 1Q14. Xention...
...a Phase IIa trial (see BioCentury, Jan. 3, 2011). Ario Pharma Ltd. , Cambridge, U.K. Xention Ltd....

...companies will jointly conduct two Phase II trials of the potassium channel Kv1.5 (KCNA5) antagonist. Xention...
...receive upfront and option fees and is eligible for milestones totaling €120 million ($162.3 million). Xention...
...the companies are planning the Phase II trials and the first will start "very soon." Xention...

...companies will jointly conduct two Phase II trials of the potassium channel Kv1.5 (KCNA5) antagonist. Xention...
...upfront and option fees and is eligible for milestones totaling EUR 120 million ($162.3 million). Xention...
...companies are currently planning the Phase II trials and the first "will start very soon." Xention...

...are at least two other programs to improve on the selectivity of marketed AF drugs. Xention Ltd....
...A/S (CSE:NEUR), Ballerup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Teijin Pharma Ltd. , Tokyo, Japan Xention Ltd....

...of 30 subjects showed that XEN-D0103 had no effect on Fridercia's corrected QT interval (QTcF). Xention Ltd....